TY  - JOUR
A1  - Ruiz-Heredia, Yanira
A1  - Sánchez-Vega, Beatriz
A1  - Onecha, Esther
A1  - Barrio, Santiago
A1  - Alonso, Rafael
A1  - Carlos Martínez-Avila, Jose
A1  - Cuenca, Isabel
A1  - Agirre, Xabier
A1  - Braggio, Esteban
A1  - Hernández, Miguel-T.
A1  - Martínez, Rafael
A1  - Rosiñol, Laura
A1  - Gutierrez, Norma
A1  - Martin-Ramos, Marisa
A1  - Ocio, Enrique M.
A1  - Echeveste, María-Asunción
A1  - Pérez de Oteyza, Jaime
A1  - Oriol, Albert
A1  - Bargay, Joan
A1  - Gironella, Mercedes
A1  - Ayala, Rosa
A1  - Bladé, Joan
A1  - Mateos, María-Victoria
A1  - Kortum, Klaus M.
A1  - Stewart, Keith
A1  - García-Sanz, Ramón
A1  - San Miguel, Jesús
A1  - José Lahuerta, Juan
A1  - Martinez-Lopez, Joaquín
T1  - Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
JF  - Haematologica
N2  - no abstract available
KW  - Copy number changes
KW  - Survival
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-227151
VL  - 103
IS  - 11
ER  - 
TY  - JOUR
A1  - Ludwig, Heinz
A1  - Delforge, Michel
A1  - Facon, Thierry
A1  - Einsele, Hermann
A1  - Gay, Francesca
A1  - Moreau, Philippe
A1  - Avet-Loiseau, Hervé
A1  - Boccadoro, Mario
A1  - Hajek, Roman
A1  - Mohty, Mohamad
A1  - Cavo, Michele
A1  - Dimopoulos, Meletios A
A1  - San-Miguel, Jesús F
A1  - Terpos, Evangelos
A1  - Zweegman, Sonja
A1  - Garderet, Laurent
A1  - Mateos, María-Victoria
A1  - Cook, Gordon
A1  - Leleu, Xavier
A1  - Goldschmidt, Hartmut
A1  - Jackson, Graham
A1  - Kaiser, Martin
A1  - Weisel, Katja
A1  - van de Donk, Niels W. C. J.
A1  - Waage, Anders
A1  - Beksac, Meral
A1  - Mellqvist, Ulf H.
A1  - Engelhardt, Monika
A1  - Caers, Jo
A1  - Driessen, Christoph
A1  - Bladé, Joan
A1  - Sonneveld, Pieter
T1  - Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
JF  - Leukemia
N2  - During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.
KW  - disease prevention
KW  - myeloma
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-237338
VL  - 32
ER  -